Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Langan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Self-citationRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092
Ständer, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2023911 · Cited by 756
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Self-citationWollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationEuropean guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Self-citationThe epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis
Dainichi, T., Kitoh, A., Otsuka, A., Nakajima, S., Nomura, T., Kaplan, D. H., & Kabashima, K. (2018) · Nature Immunology · doi:10.1038/s41590-018-0256-2 · Cited by 395
Self-citationType 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Self-citationGuttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.016 · Cited by 343
Guttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 317
Nattkemper, L. A., Tey, H. L., Valdes-Rodriguez, R., Lee, H., Mollanazar, N. K., Albornoz, C., Sanders, K. M., & Yosipovitch, G. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.12.029 · Cited by 310
“Likewise, the IL-31 receptor-targeting drug nemolizumab tested in AD should also be examined in other chronic itch diseases (Ruzicka et al., 2017).”
BackgroundAtopic dermatitis: the skin barrier and beyond
Tsakok, T., Woolf, R., Smith, C. H., Weidinger, S., & Flohr, C. (2019) · British Journal of Dermatology · doi:10.1111/bjd.16934 · Cited by 287
Physiology and Pathophysiology of Itch
Cevikbas, F., & Lerner, E. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00017.2019 · Cited by 282
Silverberg, J. I., Pinter, A., Pulka, G., Poulin, Y., Bouaziz, J.-D., Wollenberg, A., Murrell, D. F., Alexis, A., Lindsey, L., Ahmad, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.013 · Cited by 271
Self-citationA basophil-neuronal axis promotes itch
Wang, F., Trier, A. M., Li, F., Kim, S., Chen, Z., Chai, J. N., Mack, M. R., Morrison, S. A., Hamilton, J. D., Baek, J., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.033 · Cited by 264
The Itch–Scratch Cycle: A Neuroimmune Perspective
Mack, M. R., & Kim, B. S. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.001 · Cited by 255
“Moreover, in a recent phase 2 clinical trial of nemolizumab (anti-IL31RA mAb), where AD-associated pruritus was the primary outcome, the drug demonstrated significant antipruritic effects [96].”
Kabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Nakano, M., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.03.018 · Cited by 248
Self-citationNakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242
“Nemolizumab, an inhibitor of IL-31 signaling, has received attention for its antipruritic effect.(41,42) As with other cytokines, IL-4, IL-13, and IL-31 exert their biological effects via the JAK-STAT pathway.”
BackgroundEmerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis
Furue, M., Yamamura, K., Kido‐Nakahara, M., Nakahara, T., & Fukui, Y. (2018) · Allergy · doi:10.1111/all.13239 · Cited by 240
Self-citationInterleukin‐31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M., & Buddenkotte, J. (2021) · Allergy · doi:10.1111/all.14791 · Cited by 228
“73 In this phase-II clinical trial, nemolizumab (0.1, 0.5, 2 mg/kg) reduced itch by 43.7%, 59.8%, 63.1%, respectively, compared to 20.9% itch reduction with placebo (P 0.01).”
InfluentialDupilumab for treatment of atopic dermatitis
Seegräber, M., Srour, J., Walter, A., Knop, M., & Wollenberg, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1449642 · Cited by 222
Self-citationNeuro-immune crosstalk and allergic inflammation
Kabata, H., & Artis, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124609 · Cited by 215
“Regarding the potential of therapeutically targeting neuro-immune pathways, recent studies have shown that an anti–IL-31 receptor antibody, nemolizumab, successfully improves pruritus in patients with atopic dermatitis (77).”
BackgroundNew treatments in atopic dermatitis
Puar, N., Chovatiya, R., & Paller, A. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.08.016 · Cited by 199
Davidson, W. F., Leung, D. Y. M., Beck, L. A., Berin, C. M., Boguniewicz, M., Busse, W. W., Chatila, T. A., Geha, R. S., Gern, J. E., Guttman-Yassky, E., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.003 · Cited by 200
“Anti–IL-31 mAb has also been found to reduce itch.(97) However, the molecular mechanisms underlying these clinical outcomes remain unknown.”
BackgroundUnderstanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 190
New mechanism underlying IL-31–induced atopic dermatitis
Meng, J., Moriyama, M., Feld, M., Buddenkotte, J., Buhl, T., Szöllösi, A., Zhang, J., Miller, P., Ghetti, A., Fischer, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.1002 · Cited by 191
Therapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Self-citationBoguniewicz, M., Alexis, A. F., Beck, L. A., Block, J., Eichenfield, L. F., Fonacier, L., Guttman-Yassky, E., Paller, A. S., Pariser, D., Silverberg, J. I., et al. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.08.005 · Cited by 191
Guttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E., & Furue, M. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02037-2 · Cited by 187
Self-citationWilliams, K. A., Huang, A. H., Belzberg, M., & Kwatra, S. G. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.182 · Cited by 183
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis
Dubin, C., Del Duca, E., & Guttman-Yassky, E. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1940962 · Cited by 181
Neuroimmune interactions in chronic itch of atopic dermatitis
Yosipovitch, G., Berger, T., & Fassett, M. S. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15973 · Cited by 173
Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides
van Santen, S., Roach, R. E. J., van Doorn, R., Horváth, B., Bruijn, M. S., Sanders, C. J. G., de Pooter, J. C., van Rossum, M. M., de Haas, E. R. M., Veraart, J. C. J. M., et al. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.1597 · Cited by 172
Chu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Díaz Martinez, J. P., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., Wang, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.029 · Cited by 168
Immunologic, microbial, and epithelial interactions in atopic dermatitis
Brunner, P. M., Leung, D. Y. M., & Guttman-Yassky, E. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.09.055 · Cited by 165
Silverberg, J. I., Wollenberg, A., Reich, A., Thaçi, D., Legat, F. J., Papp, K. A., Gold, L. S., Bouaziz, J., Pink, A., Carrascosa, J. M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01203-0 · Cited by 174
Self-citationIL-31: A new key player in dermatology and beyond
Bağci, I. S., & Ruzicka, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.045 · Cited by 160
Self-citationAtopic dermatitis phenotypes and the need for personalized medicine
Cabanillas, B., Brehler, A.-C., & Novak, N. (2017) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000376 · Cited by 155
Furue, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113741 · Cited by 168
“Injection of the anti-IL-31 receptor A (IL-31RA) antibody nemolizumab significantly reduces the pruritus of patients with AD [66,67].”
BackgroundSelf-citationType 2 chronic inflammatory diseases: targets, therapies and unmet needs
Kolkhir, P., Akdiş, C. A., Akdiş, M., Bachert, C., Bieber, T. R. M., Canonica, G. W., Guttman‐Yassky, E., Metz, M., Mullol, J., Palomares, Ó., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00750-1 · Cited by 195
Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis
Nakashima, C., Otsuka, A., & Kabashima, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13533 · Cited by 154
Self-citationIL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases
Murdaca, G., Greco, M., Tonacci, A., Negrini, S., Borro, M., Puppo, F., & Gangemi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235856 · Cited by 161
“New efforts are now focusing on nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, with great expectations on targeted-therapy of AD [62].”
BackgroundSilverberg, J. I., Thyssen, J. P., Fahrbach, K. R., Mickle, K., Cappelleri, J. C., Romero, W., Cameron, M. C., Myers, D. E., Clibborn, C., & DiBonaventura, M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17351 · Cited by 149
Neuro-immune interactions in allergic diseases: novel targets for therapeutics
Voisin, T., Bouvier, A., & Chiu, I. M. (2017) · International Immunology · doi:10.1093/intimm/dxx040 · Cited by 136
New and Emerging Systemic Treatments for Atopic Dermatitis
Newsom, M., Bashyam, A. M., Balogh, E. A., Feldman, S. R., & Strowd, L. C. (2020) · Drugs · doi:10.1007/s40265-020-01335-7 · Cited by 136
Kabashima, K., Matsumura, T., Komazaki, H., Kawashima, M., & for the Nemolizumab JP01 andJP02 Study Group (2021) · British Journal of Dermatology · doi:10.1111/bjd.20873 · Cited by 146
Self-citationClinical practice guidelines for the management of atopic dermatitis 2018
Katoh, N., Ohya, Y., Ikeda, M., Ebihara, T., Katayama, I., Saeki, H., Shimojo, N., Tanaka, A., Nakahara, T., Nagao, M., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15090 · Cited by 131
Fleming, P., & Drucker, A. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.052 · Cited by 136
Itch: A Paradigm of Neuroimmune Crosstalk
Wang, F., & Kim, B. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.008 · Cited by 129
Zhu, T. H., Zhu, T. R., Tran, K. A., Sivamani, R. K., & Shi, V. Y. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16734 · Cited by 129
Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies
Bawany, F., Northcott, C. A., Beck, L. A., & Pigeon, W. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.12.007 · Cited by 231
Atopic Dermatitis in Animals and People: An Update and Comparative Review
Marsella, R., & Benedetto, A. D. (2017) · Veterinary Sciences · doi:10.3390/vetsci4030037 · Cited by 168
Chronic Prurigo of Nodular Type: A Review
Zeidler, C., Tsianakas, A., Pereira, M. P., Ständer, H. F., Yosipovitch, G., & Ständer, S. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2774 · Cited by 126
New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
Renert-Yuval, Y., & Guttman-Yassky, E. (2020) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.10.005 · Cited by 125
Interleukin-31 as a Clinical Target for Pruritus Treatment
Kabashima, K., & Irie, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.638325 · Cited by 133
Self-citationLeveraging Multilayered “Omics” Data for Atopic Dermatitis: A Road Map to Precision Medicine
Ghosh, D., Bernstein, J. A., Khurana Hershey, G. K., Rothenberg, M. E., & Mersha, T. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02727 · Cited by 121
FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H. (2024) · Medicinal Research Reviews · doi:10.1002/med.21991 · Cited by 117
Dendritic Cell-Mediated Th2 Immunity and Immune Disorders
Kumar, S., Ashraf, M. U., Jeong, Y., & Bae, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092159 · Cited by 130
Cork, M. J., Eckert, L., Simpson, E. L., Armstrong, A. W., Barbarot, S., Puig, L., Girolomoni, G., de Bruin-Weller, M. S., Wollenberg, A., Kataoka, Y., et al. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1612836 · Cited by 122
Self-citationMeng, J., Li, Y., Fischer, M. J. M., Steinhoff, M. S., Chen, W., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696784 · Cited by 117
Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases
Gibbs, B. F., Patsinakidis, N., & Raap, U. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01383 · Cited by 125
“However, recent data from human clinical trials using nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, clearly indicates that IL-31 is an important mediator of itch in humans too (19, 20).”
BackgroundHashimoto, T., Nattkemper, L. A., Kim, H. S., Kursewicz, C. D., Fowler, E., Shah, S. M., Nanda, S., Fayne, R. A., Paolini, J. F., Romanelli, P., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14279 · Cited by 116
Dermatitis Herpetiformis: Novel Perspectives
Antiga, E., Maglie, R., Quintarelli, L., Verdelli, A., Bonciani, D., Bonciolini, V., & Caproni, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01290 · Cited by 135
“Intriguingly, a monoclonal antibody targeting IL-31 is currently under clinical investigation in atopic dermatitis (154).”
BackgroundPruritus in allergy and immunology
Yang, T.-L. B., & Kim, B. S. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.016 · Cited by 112
Prurigo Nodularis and Its Management
Zeidler, C., Yosipovitch, G., & Ständer, S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.003 · Cited by 110
Xu, J., Zanvit, P., Hu, L., Tseng, P.-Y., Liu, N., Wang, F., Liu, O., Zhang, D., Jin, W., Guo, N., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.023 · Cited by 110
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Oda, M., Kabashima, K., & Nagata, T. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.004 · Cited by 108
Self-citationMandlik, D. S., & Mandlik, S. K. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1889583 · Cited by 129
IL-33/IL-31 Axis: A Potential Inflammatory Pathway
Salvo, E. D., Ventura-Spagnolo, E., Casciaro, M., Navarra, M., & Gangemi, S. (2018) · Mediators of Inflammation · doi:10.1155/2018/3858032 · Cited by 123
Guttman‐Yassky, E., Hanifin, J. M., Boguniewicz, M., Wollenberg, A., Bissonnette, R., Purohit, V. S., Kilty, I., Tallman, A. M., & Zielinski, M. A. (2018) · Experimental Dermatology · doi:10.1111/exd.13808 · Cited by 110
Self-citationEmerging Treatment Options in Atopic Dermatitis: Topical Therapies
Nygaard, U., Deleuran, M., & Vestergaard, C. (2017) · Dermatology · doi:10.1159/000484407 · Cited by 99
Fujii, M. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00088 · Cited by 119
Nemmer, J., Kuchner, M., Datsi, A., Oláh, P., Julia, V., Raap, U., & Homey, B. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.639097 · Cited by 107
“Recently, phase two clinical trials demonstrated therapeutic efficacy of the neutralizing IL-31RA antibody nemolizumab in patients suffering from atopic dermatitis or prurigo nodularis (2, 3).”
BackgroundResearch Techniques Made Simple: Mouse Models of Atopic Dermatitis
Kim, D. Y., Kobayashi, T., & Nagao, K. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.02.014 · Cited by 111
“IL-31, the predominant source of which are T helper type 2 cells, is associated with pruritus and disruption of the physical skin barrier, and it has recently gained attention as a novel therapeutic target in AD (Dillon et al., 2004; Feld et al., 2016; Ruzicka et al., 2017).”
BackgroundDiagnostic and treatment algorithm for chronic nodular prurigo
Ständer, H. F., Elmariah, S. B., Zeidler, C., Spellman, M. C., & Ständer, S. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.022 · Cited by 100
DOCK family proteins: key players in immune surveillance mechanisms
Kunimura, K., Uruno, T., & Fukui, Y. (2020) · International Immunology · doi:10.1093/intimm/dxz067 · Cited by 96
The Role of the Environment and Exposome in Atopic Dermatitis
Stefanovic, N., Irvine, A. D., & Flohr, C. (2021) · Current Treatment Options in Allergy · doi:10.1007/s40521-021-00289-9 · Cited by 94
The Neuroimmune Axis in Skin Sensation, Inflammation, and Immunity
Trier, A. M., Mack, M. R., & Kim, B. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801473 · Cited by 103
Taracanova, A., Tsilioni, I., Conti, P., Norwitz, E. R., Leeman, S. E., & Theoharides, T. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810133115 · Cited by 97
“Even though anti–IL-1β antibody, soluble IL-1R, and IL-1RA are available for the treatment of inflammatory diseases involving IL-1β (57, 58), there are no specific clinically available drugs that could prevent IL-1β synthesis and secretion from any cell type, including mast cells (59–62).”
BackgroundDrucker, A. M., Lam, M., Prieto‐Merino, D., Malek, R., Ellis, A. G., Yiu, Z. Z. N., Rochwerg, B. N., Giorgio, S. D., Arents, B. W. M., Mohan, T., et al. (2024) · JAMA Dermatology · doi:10.1001/jamadermatol.2024.2192 · Cited by 115
Management of Itch in Atopic Dermatitis
Pavlis, J. M., & Yosipovitch, G. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0335-4 · Cited by 101
Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis
Kuzumi, A., Yoshizaki, A., Matsuda, K. M., Kotani, H., Norimatsu, Y., Fukayama, M., Ebata, S., Fukasawa, T., Yoshizaki‐Ogawa, A., Asano, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26099-w · Cited by 90
New biological treatments for asthma and skin allergies
Eyerich, S., Metz, M., Bossios, A., & Eyerich, K. (2019) · Allergy · doi:10.1111/all.14027 · Cited by 93
Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria
Wei, L., Zhou, Q., Liu, C., Ying, M.-X., & Xu, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18187-z · Cited by 97
IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity
Takamori, A., Nambu, A., Sato, K., Yamaguchi, S., Matsuda, K., Numata, T., Sugawara, T., Yoshizaki, T., Arae, K., Morita, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25094-4 · Cited by 90
Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs
Nuttall, T. J., Marsella, R., Rosenbaum, M. R., Gonzales, A. J., & Fadok, V. A. (2019) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.254.11.1291 · Cited by 135
Treatment resistant atopic dermatitis: challenges and solutions
Johnson, B. B., Franco, A. I., Beck, L. A., & Prezzano, J. C. (2019) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s163814 · Cited by 96
Skin barrier defects in atopic dermatitis: From old idea to new opportunity
Yoshida, T., Beck, L. A., & Benedetto, A. D. (2021) · Allergology International · doi:10.1016/j.alit.2021.11.006 · Cited by 102
Genetic and Immunological Pathogenesis of Atopic Dermatitis
Schuler, C. F., IV, Tsoi, L. C., Billi, A. C., Harms, P. W., Weidinger, S., & Gudjonsson, J. E. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.10.019 · Cited by 106
A systematic review of evidence-based treatments for prurigo nodularis
Qureshi, A. A., Abate, L. E., Yosipovitch, G., & Friedman, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.09.020 · Cited by 82
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
“IL-31 Blockade The IL-31Ra antagonist nemolizumab had a highly significant antipruritic effect in patients with moderate to severe AD (64).”
BackgroundQuality of Life and Psychological Impact in Patients with Atopic Dermatitis
Talamonti, M., Galluzzo, M., Silvaggio, D., Lombardo, P., Tartaglia, C., & Bianchi, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061298 · Cited by 85
“Subjects were also asked to rate their sleep disturbance/deprivation using the visual analogue scale (sleep-VAS) with a range of 0–10 (0: no sleepiness; 10: maximum sleepiness) [11].”
Method
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.